Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study. The Journal for Immunotherapy of Cancer. 2016 March 15;4:12.
Cutaneous head and neck melanoma in OPTiM, a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma.
Phase 1 Study of CEP-37250/KHK2804, a Tumor-specific Anti-glycoconjugate Monoclonal Antibody, in Patients with Advanced Solid Tumors. Targeted Oncology.
Yu J, Liu SH, Sanchez R, Nemunaitis J, Rozengurt E, Brunicardi FC. PDX1 associated therapy in translational medicine. Ann Transl Med. 2016 Jun;4(11):214
Hypoglycemia and PDX1 Targeted Therapy. J of Endocr Disord. 2016, 2(1): 1018-24.
Phase I study of a new cancer vaccine of ten mixed peptides for advanced cancer patients.
Tumor Vaccines and Cellular Immunotherapies.
Pancreatic cancer actionable genes in precision medicine and personalized surgery. Surgeon. 2016 Jun 28. pii: S1479-666X(16)30021-X.
Review: Innovative Exploratory Clinical Approaches for Relapsed and/or Refractory Metastatic Ewing’s Sarcoma. Pediatric Cancers – Clinics in Oncology. 2016 Sept 08;1:1079.
Phase II Study of Vigil™ DNA Engineered Immunotherapy as Maintenance in Advanced Stage Ovarian Cancer. Gynecologic Oncology.